Bryce Joanne
Known title: Chief Financial OfficerCIK: 0001951845
Associated companies
Transaction History
| IRON | ▲ Buy | Grant | 18,165 | $0 | 1/10/2024 | View on chart |
| IRON | ▲ Buy | Option Exercise | 3,000 | $30K | 12/27/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 2,500 | $7K | 12/12/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 2,500 | $163K | 12/12/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 526 | $531 | 12/5/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 755 | $763 | 12/5/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 1,148 | $63K | 12/5/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 1,293 | $73K | 12/5/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 100 | $6K | 12/5/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 2,500 | $25K | 9/11/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 1,000 | $3K | 9/1/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 1,000 | $53K | 9/1/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 4,521 | $5K | 8/1/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 3,067 | $152K | 8/1/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 1,454 | $73K | 8/1/2023 | View on chart |
| IRON | ▲ Buy | Option Exercise | 7,880 | $8K | 6/28/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 4,808 | $237K | 6/28/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 4,905 | $248K | 6/28/2023 | View on chart |
| IRON | ▼ Sell | Open Market | 359 | $18K | 6/28/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Disc Medicine faces valuation scrutiny and whale activity
Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.
Disc Medicine faces valuation scrutiny and whale activity. Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.